JP2018506507A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506507A5
JP2018506507A5 JP2017528491A JP2017528491A JP2018506507A5 JP 2018506507 A5 JP2018506507 A5 JP 2018506507A5 JP 2017528491 A JP2017528491 A JP 2017528491A JP 2017528491 A JP2017528491 A JP 2017528491A JP 2018506507 A5 JP2018506507 A5 JP 2018506507A5
Authority
JP
Japan
Prior art keywords
xaa
chem
prevention
treatment
prelinker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528491A
Other languages
English (en)
Japanese (ja)
Other versions
JP6730278B2 (ja
JP2018506507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/077757 external-priority patent/WO2016083499A1/en
Publication of JP2018506507A publication Critical patent/JP2018506507A/ja
Publication of JP2018506507A5 publication Critical patent/JP2018506507A5/ja
Application granted granted Critical
Publication of JP6730278B2 publication Critical patent/JP6730278B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528491A 2014-11-27 2015-11-26 Glp−1誘導体及びその使用 Active JP6730278B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14195172.3 2014-11-27
EP14195172 2014-11-27
PCT/EP2015/077757 WO2016083499A1 (en) 2014-11-27 2015-11-26 Glp-1 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2018506507A JP2018506507A (ja) 2018-03-08
JP2018506507A5 true JP2018506507A5 (enExample) 2019-01-10
JP6730278B2 JP6730278B2 (ja) 2020-07-29

Family

ID=51982467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528491A Active JP6730278B2 (ja) 2014-11-27 2015-11-26 Glp−1誘導体及びその使用

Country Status (6)

Country Link
US (1) US11572398B2 (enExample)
EP (1) EP3226906B1 (enExample)
JP (1) JP6730278B2 (enExample)
CN (1) CN106999602B (enExample)
ES (1) ES2739289T3 (enExample)
WO (1) WO2016083499A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160021183A (ko) 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
JP6691125B2 (ja) * 2014-12-17 2020-04-28 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
PL3393496T3 (pl) 2015-12-23 2024-04-22 The Johns Hopkins University Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
WO2018113340A1 (zh) * 2016-12-20 2018-06-28 中国药科大学 多肽p11及其用途
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
PE20211417A1 (es) 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1
WO2019201333A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN112074531B (zh) * 2018-05-04 2025-04-15 诺和诺德股份有限公司 Gip衍生物及其用途
JP7422754B2 (ja) * 2018-10-26 2024-01-26 ノヴォ ノルディスク アー/エス 安定性セマグルチド組成物およびその使用
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー,リミテッド ポリペプチドコンジュゲートおよび使用の方法
CN116685599A (zh) 2020-12-16 2023-09-01 免疫医疗有限公司 多肽及其用途
TW202440619A (zh) 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
TW202304500A (zh) * 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co Ltd Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
CN117586375B (zh) * 2024-01-19 2024-07-30 苏州金顶生物有限公司 一种制备司美格鲁肽的方法
CN118546214B (zh) * 2024-07-11 2024-12-03 中国药科大学 Glp-1r受体激动多肽化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2283025T3 (es) * 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
ATE466027T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
HUP0200297A3 (en) 1999-03-17 2002-09-30 Novo Nordisk As Method for acylating peptides and the glutaminic acid derivatives as acylating agents
AU1269501A (en) 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
GB0020551D0 (en) 2000-08-22 2000-10-11 Birkett David Sprinkler system
BR0306706A (pt) 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
BRPI0407936A (pt) 2003-03-19 2006-02-21 Lilly Co Eli composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
EA012442B1 (ru) 2005-05-13 2009-10-30 Эли Лилли Энд Компани Пегилированные соединения glp-1
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー/エス Glp−1アナログ及び誘導体
BR112012024379A2 (pt) 2010-03-26 2017-01-10 Novo Nordisk As "peptídeos glucagon, seu uso, bem como composição farmacêutica"
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US9708383B2 (en) 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
BR112013015389A2 (pt) * 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
EP2723359A4 (en) 2011-06-24 2015-03-11 Amylin Pharmaceuticals Llc METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS
WO2013041678A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
KR20160021183A (ko) 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
US9498534B2 (en) 2013-07-04 2016-11-22 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
JP6691125B2 (ja) 2014-12-17 2020-04-28 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用

Similar Documents

Publication Publication Date Title
JP2018506507A5 (enExample)
RU2531590C2 (ru) Аналоги глюкагоноподобного пептида-1 и их применение
JP2014501712A5 (enExample)
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
JP2013543853A5 (enExample)
RU2013148921A (ru) Дважды ацилированные производные glp-1
JP2013517307A5 (enExample)
JP6058646B2 (ja) 多置換インスリン
JP2015517477A5 (enExample)
JP2015517478A5 (enExample)
JP2018505859A5 (enExample)
JP2014529629A5 (enExample)
JP2016529253A5 (enExample)
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2016523241A5 (enExample)
JP2016138127A (ja) 心臓病の処置
EP2729493A1 (en) Novel compounds and their effects on feeding behaviour
JP2016526012A5 (enExample)
JP2016523243A5 (enExample)
JP2014510739A5 (enExample)
JP2015513544A5 (enExample)
EP3113790A1 (en) Peptides hormone analogues derivable from preproglucagon
CA3073011A1 (en) Acylated oxyntomodulin peptide analog
CN116171283A (zh) Glp-1受体拮抗剂
EP3007721B1 (en) Non-agglomerating bioconjugates of amylin-mimetic compounds and polyethyleneglycol